Please use this identifier to cite or link to this item: http://hdl.handle.net/10668/420
Título : Hypermethylated 14-3-3-sigma and ESR1 gene promoters in serum as candidate biomarkers for the diagnosis and treatment efficacy of breast cancer metastasis
Autor : Zurita, Mercedes
Lara, Pedro C
Moral, Rosario del
Torres, Blanca
Linares-Fernández, José Luis
Ríos Arrabal, Sandra
Martínez-Galán, Joaquina
Oliver, Francisco Javier
Ruiz de Almodóvar, José Mariano
Filiación: [Zurita,M; Moral,R del; Martínez-Galán,J] Radiation Oncology, Hospital Virgen de las Nieves, Granada, Spain. [Lara,PC] Instituto Canario de Investigación del Cáncer and Servicio de Oncología Radioterápica, Hospital Dr. Negrín, Gran Canaria, Spain. [Torres,B] CIBER de Epidemiología y Salud Pública, Hospital Universitario San Cecilio, Granada, Spain. [Linares-Fernández,JL;Ríos Arrabal,S;Ruiz de Almodóvar,JM] Center for Biomedical Research and Institute of Biopathology and Regenerative Medicine, Granada University, Granada, Spain. [Oliver,FJ] Instituto de Parasitología y Biomedicina, López-Neira, CSIC, Granada, Spain. [Ruiz de Almodóvar,JM] Hospital Universitario San Cecilio, Granada, Spain.
Palabras clave : Proteinas 14-3-3
Neoplasias de la Mama
Carcinoma
Quimioterapia
Estudios de Cohortes
Metilación de ADN
ADN de Neoplasias
Supervivencia sin Enfermedad
Receptor alfa de Estrógeno
Exonucleasas
Femenino
Humanos
Proteínas de Neoplasias
Estadificación de Neoplasias
Reacción en Cadena de la Polimerasa
Valor Predictivo de las Pruebas
Regiones Promotoras Genéticas
España
Factores de Tiempo
Resultado del Tratamiento
MeSH: Medical Subject Headings::Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Intracellular Signaling Peptides and Proteins::Adaptor Proteins, Signal Transducing::14-3-3 Proteins
Medical Subject Headings::Diseases::Neoplasms::Neoplasms by Site::Breast Neoplasms
Medical Subject Headings::Diseases::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Glandular and Epithelial::Carcinoma
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Drug Therapy::Chemotherapy, Adjuvant
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies
Medical Subject Headings::Phenomena and Processes::Genetic Phenomena::Genetic Processes::DNA Methylation
Medical Subject Headings::Chemicals and Drugs::Nucleic Acids, Nucleotides, and Nucleosides::Nucleic Acids::DNA::DNA, Neoplasm
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Survival Analysis::Disease-Free Survival
Medical Subject Headings::Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::DNA-Binding Proteins::Receptors, Cytoplasmic and Nuclear::Receptors, Steroid::Receptors, Estrogen::Estrogen Receptor alpha
Medical Subject Headings::Chemicals and Drugs::Enzymes and Coenzymes::Enzymes::Hydrolases::Esterases::Exonucleases
Medical Subject Headings::Check Tags::Female
Medical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans
Medical Subject Headings::Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Neoplasm Proteins
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis::Neoplasm Staging
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Genetic Techniques::Nucleic Acid Amplification Techniques::Polymerase Chain Reaction
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Research Design::Sensitivity and Specificity::Predictive Value of Tests
Medical Subject Headings::Phenomena and Processes::Genetic Phenomena::Genetic Structures::Genome::Genome Components::Genes::Gene Components::Regulatory Elements, Transcriptional::Promoter Regions, Genetic
Medical Subject Headings::Geographicals::Geographic Locations::Europe::Spain
Medical Subject Headings::Phenomena and Processes::Physical Phenomena::Time::Time Factors
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis::Treatment Outcome
Medical Subject Headings::Chemicals and Drugs::Biological Factors::Biological Markers
Fecha de publicación : 20-May-2010
Editorial : BioMed Central
Cita Bibliográfica: Zurita M, Lara PC, Moral R del, Torres B, Linares-Fernández JL, Ríos Arrabal S, et al. Hypermethylated 14-3-3-sigma and ESR1 gene promoters in serum as candidate biomarkers for the diagnosis and treatment efficacy of breast cancer metastasis. BMC Cancer. 2010 May 20;10:217.
Abstract: Background: Numerous hypermethylated genes have been reported in breast cancer, and the silencing of these genes plays an important role in carcinogenesis, tumor progression and diagnosis. These hypermethylated promoters are very rarely found in normal breast. It has been suggested that aberrant hypermethylation may be useful as a biomarker, with implications for breast cancer etiology, diagnosis, and management. The relationship between primary neoplasm and metastasis remains largely unknown. There has been no comprehensive comparative study on the clinical usefulness of tumor-associated methylated DNA biomarkers in primary breast carcinoma and metastatic breast carcinoma. The objective of the present study was to investigate the association between clinical extension of breast cancer and methylation status of Estrogen Receptor1 (ESR1) and Stratifin (14-3-3-σ) gene promoters in disease-free and metastatic breast cancer patients. Methods: We studied two cohorts of patients: 77 patients treated for breast cancer with no signs of disease, and 34 patients with metastatic breast cancer. DNA was obtained from serum samples, and promoter methylation status was determined by using DNA bisulfite modification and quantitative methylation-specific PCR. Results: Serum levels of methylated gene promoter 14-3-3-σ significantly differed between Control and Metastatic Breast Cancer groups (P < 0.001), and between Disease-Free and Metastatic Breast Cancer groups (P < 0.001). The ratio of the 14-3-3-σ level before the first chemotherapy cycle to the level just before administration of the second chemotherapy cycle was defined as the Biomarker Response Ratio [BRR]. We calculated BRR values for the "continuous decline" and "rise-and-fall" groups. Subsequent ROC analysis showed a sensitivity of 75% (95% CI: 47.6 - 86.7) and a specificity of 66.7% (95% CI: 41.0 - 86.7) to discriminate between the groups for a cut-off level of BRR = 2.39. The area under the ROC curve (Z = 0.804 ± 0.074) indicates that this test is a good approach to post-treatment prognosis. Conclusions: The relationship of 14-3-3-σ with breast cancer metastasis and progression found in this study suggests a possible application of 14-3-3-σ as a biomarker to screen for metastasis and to follow up patients treated for metastatic breast cancer, monitoring their disease status and treatment response.
URI: http://hdl.handle.net/10668/420
Versión del editor : http://www.biomedcentral.com/1471-2407/10/217
DOI: 10.1186/1471-2407-10-217
ISSN : 1471-2407
Appears in Collections:01- Artículos - Hospital San Cecilio
01- Artículos - Hospital Virgen de las Nieves

Files in This Item:
File Description SizeFormat 
Zurita_Hypermethylated.pdfArtículo principal1 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons